title: [The place of acetylsalicylic acid in the modern cardiovascular pharmacotherapy].
abstract: Acetylsalicylic acid (ASA) is effective antiplatelet agent in many groups of patients with cardiovascular disorders. Efficacy and safety of ASA was confirmed in many trials and meta-analyses. But the optimal dose of ASA in different conditions is still uncertain. ASA is effective in all forms of coronary heart disease. Most prominent effect is observed in patients with acute coronary syndrome without ST elevation and with myocardial infarction. Also, ASA is a necessary component of therapy in patients before and after coronary angioplasty and stenting. ASA plays important role in the management of patients with peripheral arterial disease. Today, ASA is the only antiplatelet drug recommended for the treatment of ischemic stroke. Also, ASA is effective as a method of secondary prophylaxis after ischemic stroke or transitory ischemic attack. As a method of primary prophylaxis, ASA is indicated for patients with annual risk of coronary events 1.5% and more. But, if the annual risk of coronary events is less than 1%, prophylactic treatment with ASA is contraindicated. Thus, ASA must be prescribed to all patients with high risk of cardiovascular complications, if contraindications are absent.
authors.affiliation: I M Sechenov Moscow Medical Academy, ul Bolshaya Pirogovskaya 2/6, 119881, Moscow, Russia.
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Giliarov
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology; D014943:Global Health; D006801:Humans; D009017:Morbidity / Q000639:trends; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin